Br J Cancer: HOX Gene: Potential Therapeutic Target for Adrenal Corticocarcinoma

Adrenal cortoma is a relatively common disease with a prevalence of 1-10%.
most of these are benign adenomas, but in rare cases (up to 2 cases per million per year) they develop adrenal cortique cancer (ACC), an invasive disease with a low five-year survival rate.
current ACC treatments include surgery for non-metastasis diseases and mitotane therapy, but have limited efficacy in late-stage patients.
, understanding the signaling path paths that drive ACC development is critical to developing more effective treatments and predicting individual outcomes.
study aims to explore the role and contribution of transcription factor HOXB9 and other HOX factors in the development of ACC.
HOXB9 and invasive ACC used genetically modified mouse models to analyze Hoxb9's role in the development of adrenal tumors.
to understand the expression of the HOX gene and its relationship to disease by analyzing the transcriptional group data of the patient.
new treatment options through drug response studies of various adrenal cortital models.
of human ACC data sets showed that high levels of expression of HOXB9 and other HOX factors were associated with poor prognostication in patients.
researchers found that over-expression of Hoxb9 in the adrenal corties of mice activated by Ctnnb1 can lead to larger adrenal tumors.
the esotype is preferred in male mice, characterized by increased cell proliferation and elevated expression levels of cell cycle-related genes, including Ccne1.
further studies have shown that the survival of adrenal tumor cells depends on HOX function and is sensitive to specific peptide inhibitors.
accreditation of ACC cells to HOX-PBX functional inhibition, the results show that Hoxb9 can promote the development of adrenal tumors in a gender-dependent manner, and HOX factor has been identified as a potential drug target or could be a new treatment for ACC.
。